2023 Fiscal Year Final Research Report
Search for new biomarkers in asthma and COPD: focus on NGAL and sRAGE
| Project/Area Number |
20K17176
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 53030:Respiratory medicine-related
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | ACO / 喘息 / COPD / バイオマーカー / Ⅱ型肺胞上皮細胞 |
|---|
| Outline of Final Research Achievements |
Repeated intratracheal administration of papain was investigated to see if a mouse model reflecting the pathology of ACO could be created and was shown to produce emphysema, allergic airway inflammation and airway hyperresponsiveness. The behaviour of biomarkers such as NGAL and sRAGE in BALF was also consistent with that in humans and was considered a good mouse model. Single Cell RNA Seq Analysis of type II alveolar epithelial cells showed a marked increase in the proportion of cells in the Atf5+, Il4i1+ and Meg3+ clusters in the ACO model, suggesting that they may be responsible for the pathogenesis. High expression of NGAL was widely observed in each cluster.
|
| Free Research Field |
喘息、COPD
|
| Academic Significance and Societal Importance of the Research Achievements |
過去にACOの病態を良好に反映したマウスモデルが開発されておらず、病態解明に向けて障壁となっていたが、本研究により良好なACOマウスモデルが樹立され、さらに新たな病態形成を担う可能性のある分子を認めた。また、NGALのバイオマーカーとしての可能性を示唆する結果を得た。本マウスモデルを用いることで、ACOにおけるバイオマーカーや治療標的分子の同定に向けた研究が期待でき、現在解析を進めている。
|
